BlackRock’s Valion Bio VBIO Stock Holding History

BlackRock’s Portfolio VBIO Stock Details VBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6	Closed	-$15K	–	5982
2022 Q1	$15K	Buy	6 +1	+20%	+$3.27K	﹤0.01%	5603
2021 Q4	$35K	Buy	+5	New	+$36.7K	﹤0.01%	5466

Other funds holding VBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock's VBIO Position: Q2 2022 in Review

BlackRock sold out of Valion Bio (VBIO) in Q2 2022, closing a stake of 6 shares — an estimated $15K sold.

BlackRock first reported a position in VBIO in Q4 2021 and held it in 2 quarters. The position peaked at $35K in Q4 2021. 4 funds tracked by Wall St. Rank hold VBIO as of Q2 2022.

BlackRock reported no remaining Valion Bio position as of Q2 2022 after selling out during the quarter.
BlackRock sold 6 Valion Bio shares in Q2 2022, an estimated $15K.
BlackRock first reported a position in Valion Bio in Q4 2021 and held it in 2 quarters.
BlackRock's Valion Bio position peaked at $35K in Q4 2021.
4 funds tracked by Wall St. Rank held Valion Bio as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.